Page 1007 - Read Online

Page 10 of 10 Kim et al. Hepatoma Res 2020;6:85 I http://dx.doi.org/10.20517/2394-5079.2020.96

59. Brouwers MC, Simons N, Stehouwer CD, Koek GH, Schaper NC, Isaacs A. Relationship between nonalcoholic fatty liver disease
susceptibility genes and coronary artery disease. Hepatol Commun 2019;3:587-96.
60. Kraft P, Wacholder S, Cornelis MC, et al. Beyond odds ratios - communicating disease risk based on genetic profiles. Nat Rev Genet
2009;10:264-9.
61. Chatterjee N, Shi J, García-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat
Rev Genet 2016;17:392.
62. Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic
fatty liver. J Intern Med 2018;283:356-70.
63. Krawczyk M, Liebe R, Lammert F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond.
Gastroenterology 2020;158:1865-80.e1.
64. Vespasiani-Gentilucci U, Gallo P, Dell’Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A. Promoting genetics in non-alcoholic fatty
liver disease: combined risk score through polymorphisms and clinical variables. World J Gastroenterol 2018;24:4835.
65. Hyysalo J, Männistö VT, Zhou Y, et al. A population-based study on the prevalence of NASH using scores validated against liver
histology. J Hepatol 2014;60:839-46.
66. Kim DY, Park JY. Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed? Hepatobiliary Surg
Nutr 2019;8:522.
67. Zhou Y, Orešič M, Leivonen M, et al. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels
of lipids and metabolites. Clin Gastroenterol Hepatol 2016;14:1463-72.e6.
68. Romeo S, Sentinelli F, Dash S, et al. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic
injury in individuals of European descent. Int J Obes 2010;34:190-4.